Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

James Talks

Showing results (51-60 of 65) with videos related to

Pageof 7
Sort By:
Eye (London, England)|April 2, 2021
Fluid as a critical biomarker in neovascular age-related macular degeneration management: literature review and consensus recommendationsLaurent Kodjikian, Mariacristina Parravano, Andreas Clemens, et al.
Eye (London, England)|May 12, 2025
Visual outcome following initiation of first injection versus after three monthly doses of aflibercept 2 mg for treatment naïve age-related macular degeneration to inform clinical trial designs: PRECISE Report No. 6Swati Chandak, Sarega Gurudas, Raheeba Pakeer Muhammed, et al.
Eye (London, England)|May 6, 2024
Impact of treat and extend criteria on proportions that can be extended after loading phase of 2 mg aflibercept therapy for neovascular age related macular degeneration: PRECISE Report 5Sridevi Thottarath, Sarega Gurudas, Swati Chandak, et al.
Ophthalmology Science|June 30, 2026
Tropomyosin-Related Kinase Receptor Type B Agonism in Geographic Atrophy-The Translational Challenges from Preclinical Data to a First-in-Human TrialDavid Brown, Oliver Zeitz, Clare Bailey, et al.
Eye (London, England)|December 15, 2023
Baseline characteristics of eyes with early residual fluid post loading phase of aflibercept therapy in neovascular AMD: PRECISE study report 3Shruti Chandra, Sarega Gurudas, Ian Pearce, et al.
Eye (London, England)|April 23, 2024
Subretinal transient hyporeflectivity in neovascular age-related macular degeneration and its response to a loading phase of aflibercept: PRECISE report 4Andrea Montesel, Raheeba Pakeer Muhammed, Swati Chandak, et al.
Eye (London, England)|October 23, 2025
Real-world treatment patterns and visual outcomes of faricimab in patients with diabetic macular oedema in the UK at 12 months: the FARWIDE-DMO studyTunde Peto, Ian Pearce, James Talks, et al.
Ophthalmology. Retina|June 13, 2025
Deep-learning algorithm for the diagnosis and prediction of hydroxychloroquine retinopathy: An International, multi-institutional studyPeter Woodward-Court, Jeffry Hogg, Terry Lee, et al.
Eye (London, England)|October 18, 2023
Associations of presenting visual acuity with morphological changes on OCT in neovascular age-related macular degeneration: PRECISE Study Report 2Shruti Chandra, Sarega Gurudas, Benjamin J L Burton, et al.
Journal of Clinical Medicine|April 28, 2023
A Multi-Modal AI-Driven Cohort Selection Tool to Predict Suboptimal Non-Responders to Aflibercept Loading-Phase for Neovascular Age-Related Macular Degeneration: PRECISE Study Report 1Michal Chorev, Jonas Haderlein, Shruti Chandra, et al.
Pageof 7

Showing results (51-60 of 65) with videos related to

Sort By:
Pageof 7
Eye (London, England)|April 2, 2021
Fluid as a critical biomarker in neovascular age-related macular degeneration management: literature review and consensus recommendationsLaurent Kodjikian, Mariacristina Parravano, Andreas Clemens, et al.
Eye (London, England)|May 12, 2025
Visual outcome following initiation of first injection versus after three monthly doses of aflibercept 2 mg for treatment naïve age-related macular degeneration to inform clinical trial designs: PRECISE Report No. 6Swati Chandak, Sarega Gurudas, Raheeba Pakeer Muhammed, et al.
Eye (London, England)|May 6, 2024
Impact of treat and extend criteria on proportions that can be extended after loading phase of 2 mg aflibercept therapy for neovascular age related macular degeneration: PRECISE Report 5Sridevi Thottarath, Sarega Gurudas, Swati Chandak, et al.
Ophthalmology Science|June 30, 2026
Tropomyosin-Related Kinase Receptor Type B Agonism in Geographic Atrophy-The Translational Challenges from Preclinical Data to a First-in-Human TrialDavid Brown, Oliver Zeitz, Clare Bailey, et al.
Eye (London, England)|December 15, 2023
Baseline characteristics of eyes with early residual fluid post loading phase of aflibercept therapy in neovascular AMD: PRECISE study report 3Shruti Chandra, Sarega Gurudas, Ian Pearce, et al.
Eye (London, England)|April 23, 2024
Subretinal transient hyporeflectivity in neovascular age-related macular degeneration and its response to a loading phase of aflibercept: PRECISE report 4Andrea Montesel, Raheeba Pakeer Muhammed, Swati Chandak, et al.
Eye (London, England)|October 23, 2025
Real-world treatment patterns and visual outcomes of faricimab in patients with diabetic macular oedema in the UK at 12 months: the FARWIDE-DMO studyTunde Peto, Ian Pearce, James Talks, et al.
Ophthalmology. Retina|June 13, 2025
Deep-learning algorithm for the diagnosis and prediction of hydroxychloroquine retinopathy: An International, multi-institutional studyPeter Woodward-Court, Jeffry Hogg, Terry Lee, et al.
Eye (London, England)|October 18, 2023
Associations of presenting visual acuity with morphological changes on OCT in neovascular age-related macular degeneration: PRECISE Study Report 2Shruti Chandra, Sarega Gurudas, Benjamin J L Burton, et al.
Journal of Clinical Medicine|April 28, 2023
A Multi-Modal AI-Driven Cohort Selection Tool to Predict Suboptimal Non-Responders to Aflibercept Loading-Phase for Neovascular Age-Related Macular Degeneration: PRECISE Study Report 1Michal Chorev, Jonas Haderlein, Shruti Chandra, et al.
Pageof 7